title: [Treatment of refractory or recurrent Clostridium difficile infection].
abstract: The incidence and severity of Clostridium difficile infection (CDI) has increased over the past decades. It is related to the emergence of hypervirulent strains and increased use of antibiotics. The incidence of refractory CDI to standard therapies and the risk for recurrent CDI are also increasing. Current guidelines recommend the first recurrence to be treated with the same agent used for the initial episode. However, data are lacking to support any particular treatment strategy for severe refractory CDI or cases with multiple recurrence. Treatments currently available for CDI are inadequate to prevent recurrence. Widely used method for managing a subsequent recurrence involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI are use of other antibiotics such as fidaxomicin, nitazoxanide, rifaximin, tigecycline, and teicoplanin. There are efforts to recover gut microflora and to optimize immune response to CDI. These include use of probiotics, fecal microbiota transplantation, intravenous immunoglobulin, monoclonal antibodies directed against C. difficile toxins, and active vaccination. However treatment of patients with refractory CDI and those with multiple CDI recurrences is based on limited clinical evidence, and there is an ongoing need for continued research to improve the outcomes these patients.
authors.affiliation: Department of Internal Medicine, Seoul St. Mary's Hospital, 222 Banpodae-ro, Seocho-gu, Seoul 137-040, Korea. viper@catholic.ac.kr
authors.forename: Sang Woo
authors.initials: SW
authors.lastname: Kim
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects / Q000472:pathogenicity; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D012008:Recurrence; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D014640:Vancomycin